Abratt R P, Shepherd L C, Pontin A R, Barnes R D, Ball H S
Department of Radiation Oncology, University of Cape Town.
S Afr J Surg. 1998 Aug;36(3):87-9; discussion 89-90.
The aim of this study of patients undergoing cystectomy for invasive transitional cell carcinoma of the bladder was to compare clinical and pathological staging and to review factors that predict survival.
Sixty-three patients (73% male) underwent radical cystectomy between January 1988 and February 1994. The mean age was 61 years (range 33-77 years).
Of the patients 14% had clinical and 24% pathological stage T1 disease; figures for T2 disease were 24% and 6%, respectively, for T3 disease 46% and 45%, and for T4 disease 16% and 25%. For T1 and T4 disease the clinical stage predicted the pathological stage in over 80% of cases, and for patients with T3 disease the predictive value of clinical staging was 68%; in no patient with clinical stage T2 disease was this confirmed at cystectomy. The prevalence of tumour infiltration of the lymph glands on histological examination of the cystectomy specimen correlated more closely with pathological stage than with clinical stage. For clinical and pathological staging, respectively, the prevalences were 0% and 0%, for T1, 27% and 0% for T2, 20% and 29% for T3, and 40% and 38% for T4. The overall survival rate (life-table method) was 33% at a median follow-up of 42 months in the surviving patients. No patient with tumour infiltration of the lymph glands survived. Survival also correlated more closely with pathological than with histological stage. For clinical and pathological stage T1 disease the 5-year survival rates were 73% and 91%, respectively; for T2 the rates were 27% and 75%, for T3 32% and 31%, and for T4 28% and 29%. The operative mortality rate was 2% and the rate of recurrence of local disease 10%.
Survival after cystectomy correlates more closely with pathological than with clinical stage of disease. The accuracy of clinical staging in T2 disease is poor. Cystectomy is the standard against which other treatments for bladder cancer must be measured.
本研究旨在对因浸润性膀胱移行细胞癌而接受膀胱切除术的患者进行临床和病理分期比较,并回顾预测生存的因素。
1988年1月至1994年2月期间,63例患者(73%为男性)接受了根治性膀胱切除术。平均年龄为61岁(范围33 - 77岁)。
患者中,14%临床分期为T1期,24%病理分期为T1期;T2期患者的相应数据分别为24%和6%,T3期为46%和45%,T4期为16%和25%。对于T1和T4期疾病,超过80%的病例临床分期可预测病理分期;对于T3期疾病患者,临床分期的预测价值为68%;在临床分期为T2期的患者中,膀胱切除术中均未得到证实。膀胱切除标本组织学检查显示淋巴结肿瘤浸润的发生率与病理分期的相关性比与临床分期更密切。临床分期和病理分期中,T1期的发生率分别为0%和0%,T2期为27%和0%,T3期为20%和29%,T4期为40%和38%。存活患者中位随访42个月时,总生存率(生命表法)为33%。无淋巴结肿瘤浸润患者存活。生存与病理分期的相关性也比与组织学分期更密切。临床和病理分期为T1期疾病的5年生存率分别为73%和91%;T2期分别为27%和75%,T3期为32%和31%,T4期为28%和29%。手术死亡率为2%,局部疾病复发率为10%。
膀胱切除术后的生存与疾病的病理分期而非临床分期相关性更密切。T2期疾病临床分期的准确性较差。膀胱切除术是衡量其他膀胱癌治疗方法的标准。